For the operation of the group insurance commission; provided, that on a monthly basis, the commission shall provide the caseload forecasting office with enrollment data and any other information pertinent to caseload forecasting; provided further, that the information shall be provided in a manner that meets all applicable federal and state privacy requirements; provided further, that the commission shall submit quarterly reports to the house and senate committees on ways and means that shall include, but not be limited to: (i) any proposed plan changes accompanied by a detailed rationale for such changes; (ii) a detailed delineation of any estimated deficiencies or reversions in the current fiscal year, detailed by item; and (iii) a projection of any funding changes for the following fiscal year, detailed by item; provided further, that not later than September 25, 2026 the first such report shall be submitted; provided further, that the commission shall provide all materials presented at any public meetings hosted by the commission to the house and senate committees on ways and means not later than 15 days after the public meeting; provided further, that not less than $300,000 shall be expended to the Harvard T.H. Chan School of Public Health to conduct a study and issue a report on the impact on health status and health care utilization as a result of discontinuing commercial and public health insurance coverage for glucagon--like peptide--1 medications for patients with obesity; provided further, that such funds shall be made available until June 30, 2029; provided further, that the report shall be submitted to the executive office for administration and finance, the joint committee on health care financing and the house and senate committees on ways and means and shall include, but not be limited to, an analysis of: (a) the impacts of discontinued coverage for glucagon--like peptide--1 medications on the utilization of health care services, total medical spending and enrollee out--of--pocket spending; (b) how individuals and providers respond to discontinued coverage of glucagon--like peptide--1 medications including, but not limited to, whether individuals are paying for the medication out of pocket or the prescriber is recoding patient diagnoses; (c) how the impacts vary across groups of individuals; and (d) the comparison of health outcomes and total medical spending between enrollees that have lost coverage of glucagon--like peptide--1 medications and enrollees who have maintained coverage for glucagon--like peptide--1 medications for obesity management; and provided further, that not later than February 7, 2027, the commission shall submit a report to the executive office for administration and finance, the joint committee on health care financing and the house and senate committees on ways and means detailing the preliminary findings of the study
